Live Breaking News & Updates on Ma203cd8

Stay updated with breaking news from Ma203cd8. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME

IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics' proprietary CD8aß co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 ....

United States , Twitterand Linkedin , Eva Mulder , Cedrik Britten , Anja Heuer , Immatic Actengine , Texasand Tuebingen , Corporate Communications , Trophic Communications , Chief Medical Officer , All Immatic , Stem Cell Therapeutics Research Laboratory , Adoptive Cell Therapies , Looking Statements , Investor Relations ,